Wilson bought by Alexion

Wilson Therapeutics AB is to be bought by Alexion Pharmaceuticals Inc for $855 million in a deal that underscores the potential of the Swedish company’s lead product for Wilson disease, a rare genetic disorder that prevents the body from regulating copper. The disease can lead to liver and brain damage.

Full text available to subscribers only. Click here for information on subscribing to MedNous.